Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients

Andrew M. Courtwright, Anthony M. Lamattina, Pierce H. Louis, Anil J. Trindade, Patrick Burkett, Jewel Imani, Shikshya Shrestha, Miguel Divo, Steve Keller, Ivan O. Rosas, Hilary J. Goldberg, Souheil El-Chemaly

Research output: Contribution to journalArticlepeer-review


Hyaluronan (HA) is associated with innate immune response activation and may be a marker of allograft dysfunction in lung transplant recipients. This was a prospective, single center study comparing levels of bronchioalveolar lavage (BAL) and serum HA and the HA immobilizer LYVE-1 in lung transplant recipients with and without acute cellular rejection (ACR). Chronic lung allograft dysfunction (CLAD)-free survival was also evaluated based on HA and LYVE-1 levels. 78 recipients were enrolled with a total of 115 diagnostic biopsies and 1.5 years of median follow-up. Serum HA was correlated with BAL HA (r = 0.25, p = 0.01) and with serum LYVE-1 (r = 0.32, p = 0.002). There was significant variation in HA and LYVE-1 over time, regardless of ACR status. Levels of serum HA (median 74.7 vs 82.7, p = 0.69), BAL HA (median 149.4 vs 134.5, p = 0.39), and LYVE-1 (mean 190.2 vs 183.8, p = 0.72) were not associated with ACR. CLAD-free survival was not different in recipients with any episode of elevated serum HA (HR = 1.5, 95% CI = 0.3–7.7, p = 0.61) or BAL HA (HR = 0.94, 95% CI = 0.2–3.6, p = 0.93). These results did not differ when stratified by bilateral transplant status. In this small cohort, serum HA, BAL HA, and LYVE-1 levels are not associated with ACR or CLAD-free survival in lung transplant recipients.

Original languageEnglish (US)
Article number9003
JournalScientific reports
Issue number1
StatePublished - Dec 1 2019
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients'. Together they form a unique fingerprint.

Cite this